Target Now is an oncology testing service that utilizes cutting-edge molecular profiling techniques, including DNA microarray, proprietary immunohistochemistries (IHC), fluorescent in-situ hybridization (FISH) and sequencing analyses, to provide molecular profiling information about a tumor as an aid to a patient’s oncologist. Each test report provides information on the molecular targets present in the tumor for which there are believed to be associated therapies based on published literature. As well, the report provides other additional information on the molecular profile of the patient’s tumor.

Target Now can be of value for:

• Patients refractory to second line standard of care therapy;
  
• Patients with rare tumor types having less well-defined or ‘research only’ treatment protocols; or
  
• Select patients diagnosed with very aggressive cancers having an very high mortality rate with first line standard of care therapy (e.g., pancreatic cancer); or
• Select patients that have yet to undergo first line therapy but have significant co-morbidities
  that could preclude standard treatment options.

Given the rapid pace of discoveries of biomarkers and their associations with therapies, Target Now is constantly evolving to incorporate the most current research findings. The clinicians who request Target Now are invited to join the Target Now Physician Network, whereby they can offer insight into their experiences with the test as well as request research into new markers and therapeutic associations. Additionally, in certain circumstances, Target Now may be accessed through our ongoing research study.

Flexible testing platform for all malignancies

Solid and non-solid tumors
      • Formalin fixed paraffin embedded (FFPE) and/or fresh-frozen tissue
              – DNA microarray (gene expression)
              – Protein immunohistochemistry (IHC) analysis
              – FISH
              – Gene sequencing
              – Light microscopic (and molecular) review of the tumor diagnosis

Personalized integrated report

• Quantitative results
• List of potentially druggable or resistant molecular target(s) common to tumors typically independent of lineage
                  – Evidence-based approach for target selection
• List of associated therapeutics from research (for informational purposes only)
                  – Integration of relevant scientific literature and research review

Provider reimbursement

Reimbursed by Medicare and other third party payors
A balance bill to patients is not sent except co-pays and deductibles as required by law.

For more information, contact Caris Dx at 800-901-5177 or www.targetnow.com